A: CT ofthe sinuses shows ethmoid sinusitis and a recurring infraorbital ethmoid cell infection. Inset shows a mucocele within the infraorbital ethmoid cell. B: A transnasal telescopic view (4 mm, 0°) shows a left polypoidadhesionfrom prior surgery.Note the patentmiddle meatal .antrostomy. C: An anterior telescopic view (4 mm, 30°) through a mini-Caldwell-Luc opening shows the mucocele in the anterior infraorbital ethmoid cell. V: Another anterior telescopic view (4 mm, 30°) shows the removal ofthe mucocele with a cup forceps.
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A white, 37-year-old woman came to the office with a complaint of left-sided headaches. Despite earlier treatment with multiple antibiotics, antifungal medications, and endoscopic sinus surgery, she continued to experience persistent cephalalgia.
Computed tomography (CT) of the sinuses showed an opacification of the left ethmoid and infraorbital ethmoid cells (Haller cells) and a roundish mass within the Haller cells (figure, A). The remainder of the sinuses were clear of disease, and the antrostomy sites were patent. Nasal Long-term carcinogenicity studies in mice and rats have been completed forciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250mg/kg (rats) were administered/or upto 2 years, there was noeVIdence that ciprofloxacin had any carcinogenic ortumorigenic effects Inthese species. Nolong term studres ofCIPRO® HC OTIC suspension have been performed to evaluate carcinogenic potential. Fertility studies performed In rats at oral doses at ciproftoxacin up to 100 mg/kg/day revealed no evdence of impairment. This would beover 1000 times the maximum recommended clinical dose of ototopical oprofloxacm based upon body surtace area, assuming total absorption ofclproflnxaon fromthe ear ofapatient treated with CIPRO® HC OTIC twice perday. Long term studies have not been pertormed to evaluate the carcinogenic potential or the effect on fertility oftopical hydrocortisone. Mutagenicity studies with hydrocortisone were negative. Pregnancy: Teratogenic Effects, Pregnancy Category C: Reproduction studies have been pertormed in rats and mice usmq oral doses of upto 100mg/kg and IV doses upto 30mg/kg and have revealed noevidence of harm to thefetus as a resuit of ciprofloxacin. In rabbits, ciprofioxacin (30and 100mg/kg orally) produced gastrointestinal disturbances resulting Inmaternal weight loss and anIncreased incidence ofabortion, butnoteratogenicity was observed ateither dose. After intravenous administration ofdoses upto20mg/kg, nomaternal tOXICity was produced mtherabbit, and noembryotoxicity orteratogenicity was observed. Corncosterotds are generally teratocemc In laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to beteratogenIC after dermal application in laboratory animals Animal reproduction studies have not been conducted With CIPRO® HC OTIC Noadequate and well controlled studies have been performed In pregnant women. Caution should be exercised when CIPRD® HC OTIC IS used bya pregnant woman Nursing Mothers: Clprofloxacln is excreted in human milkWith systemic use. It is notknown whether ciprofloxacin is excreted Inhuman milkfollowing topical oticadministration. Because ofthepotential for serious adverse reactions In nursing intants, adecision should bemade whether to disconunue nursmg or to discontinue thedrug, taking Into account theimportance 01 thedrug tothemother Pediatric use: The satety and efficacy of CIPRQ® HC OTIC have been established in pediatric patients 2 years and older (131 patients) In adequate and well-controlled clinical tnals. Although no data are available on patients less than age 2 years, there are no known safety concerns or differences In the disease process inthlspopulation which would preclude use ofthisproduct Inpatients one year and older See DOSAGE AND ADMINISTRATION. ADVERSE REACTIONS In Phase 3 clinical trials, a total of 564 patients were treated With CIPRD® HC OTIC. Adverse events with at least remote relationship to treatment included headache (12%)and pruntus (0.4%). (figure, B) . The patient underwent a left endoscopic ethmoidectomy with a left mini-Caldwell-Luc procedure in order to gain access to the opacified infraorbital ethmoid cell. A 30°t elescope was passed through the mini-Caldwell-Luc opening, and the infraorbital ethmoid cell was visualized (figure, C). The Haller cell was resected and was found to contain a mucocele full of thick, yellow mucus (figure, D). Following this procedure, the patient has remained symptom-free for 9 months.
The 18 lh-century Swiss anatomist Albrecht von Haller described the ethmoid pneumatization of the inferior bony wall of the orbit.' A pneumatized infraorbital ethmoid cell is today called a Haller cell. A diagnosis of a Haller cell cannot be made during transnasal endoscopy, because this cell is lateral to the lateral nasal wall. Haller cells make up the posterior and superior wall of the ethmoid infundibulum. When the Haller cells become enlarged, they can cause obstruction of the ethmoid infundibulum and lead to maxillary sinusitis."
A diagnosis of Haller cell is easily made on coronal sinus CT, which is the primary means of diagnosing anatomic variations. The integrity of the surrounding lamina papyracea should be inspected to ensure the absence of any orbital fat dehiscence within the Haller cell. Cloudiness or a soft-tissue shadow should be looked for. If symptoms and findings persist, anterior rhinoscopy via a canine fossa or a mini -Caldwell-Luc approach should be performed and pathology should be removed. A transnasal telescopic approach does not show a lesion in the anteriormost position of a Haller cell.
In this case, we suspected that a mucocele was present in an infraorbital ethmoid cell, and this was confirmed by the sinus CT and by the mini-Caldwell-Luc approach. Haller cell mucocele or empyema with purulent secretions can cause a constant or episodic impingement of the ethmoid infundibulum.' It is important to identify Haller cells on the preoperative CT and to resect them if they are symptomatic.
